Patents by Inventor David B. Volkin

David B. Volkin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA vaccine formulations
    Patent number: 7927870
    Abstract: This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.
    Type: Grant
    Filed: May 10, 2006
    Date of Patent: April 19, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: David B. Volkin, Robert K. Evans, Mark Bruner
  • Adenovirus formulations
    Patent number: 7456009
    Abstract: The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration. These formulations comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or a chelating agent to inhibit free radical oxidation.
    Type: Grant
    Filed: March 3, 2005
    Date of Patent: November 25, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Evans, David B. Volkin, Lynne A. Isopi
  • Adenovirus formulations
    Patent number: 7351415
    Abstract: The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration. These formulations comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or a chelating agent to inhibit free radical oxidation.
    Type: Grant
    Filed: March 2, 2004
    Date of Patent: April 1, 2008
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Evans, David B. Volkin
  • Polynucleotide vaccine formulations
    Publication number: 20040242522
    Abstract: The present invention relates to a novel vaccine formulation comprising nucleic acid molecules and an mineral-based adjuvant provided in a biologically effective concentration so as to improve induction of an immune response subsequent to vaccination which correlates to expression of one or more specific antigens encoded by the nucleic acid molecule.
    Type: Application
    Filed: January 26, 2004
    Publication date: December 2, 2004
    Inventors: David B. Volkin, Robert K. Evans, Jeffrey B. Ulmer, Michael J. Caulfield
  • Adenovirus formulations
    Publication number: 20040166122
    Abstract: The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration. These formulations comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or a chelating agent to inhibit free radical oxidation.
    Type: Application
    Filed: March 2, 2004
    Publication date: August 26, 2004
    Inventors: Robert K. Evans, David B. Volkin
  • DNA vaccine formulations
    Publication number: 20040138165
    Abstract: This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.
    Type: Application
    Filed: October 30, 2003
    Publication date: July 15, 2004
    Applicant: Merck & Co., Inc.
    Inventors: David B. Volkin, Robert K. Evans, Mark Bruner
  • Adenovirus formulations
    Publication number: 20040033239
    Abstract: The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration. These formulations comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or a chelating agent to inhibit free radical oxidation.
    Type: Application
    Filed: August 20, 2002
    Publication date: February 19, 2004
    Inventors: Robert K Evans, David B Volkin
  • Rotavirus vaccine formulations
    Patent number: 6616931
    Abstract: The present invention provides liquid and lyophilized formulations of vaccines against rotavirus infection and methods of their preparation. The formulations include buffering agents appropriate for oral administration of rotavirus vaccines. The formulations also include compounds to stabilize of the vaccine compositions against loss of potency.
    Type: Grant
    Filed: August 3, 2000
    Date of Patent: September 9, 2003
    Assignee: Merck & Co., Inc.
    Inventors: Carl J. Burke, David B. Volkin
  • DNA vaccine formulations
    Publication number: 20020156037
    Abstract: This invention relates to novel methods and formulations of nucleic acid pharmaceutical products, specifically formulations of nucleic acid vaccine products and nucleic acid gene therapy products. The formulations of the disclosure stabilize the conformation of DNA pharmaceutical products.
    Type: Application
    Filed: September 7, 2001
    Publication date: October 24, 2002
    Applicant: Merck & Co., Inc.
    Inventors: David B. Volkin, Robert K. Evans, Mark Bruner
  • Rotavirus vaccine formulations
    Patent number: 6403098
    Abstract: The present invention provides novel liquid and lyophilized formulations of vaccines against rotavirus infection and methods of their preparation. The formulations include buffering agents appropriate for oral administration of rotavirus vaccines. The formulations also include compounds to stabilize of the vaccine compositions against loss of potency.
    Type: Grant
    Filed: August 3, 1999
    Date of Patent: June 11, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Carl J. Burke, David B. Volkin
  • DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof
    Patent number: 6387695
    Abstract: The present invention relates to nucleic acid formulations of pharmaceutical products which comprise citrate and/or triethanolamine in concentrations which enhance stability of the nucleic acid. These formulations are suited for situations where prolonged storage occurs during the distribution and/or storage period prior to use.
    Type: Grant
    Filed: December 22, 1998
    Date of Patent: May 14, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Robert K. Evans, David B. Volkin, Mark W. Bruner, Zheng Xu
  • Polynucleotide vaccine formulations
    Publication number: 20020045594
    Abstract: The present invention relates to a novel vaccine formulation comprising nucleic acid molecules and an mineral-based adjuvant provided in a biologically effective concentration so as to improve induction of an immune response subsequent to vaccination which correlates to expression of one or more specific antigens encoded by the nucleic acid molecule.
    Type: Application
    Filed: September 12, 2001
    Publication date: April 18, 2002
    Applicant: Merck & Co., Inc.
    Inventors: David B. Volkin, Robert K. Evans, Jeffrey B. Ulmer, Michael J. Caulfield
  • Adenovirus formulations
    Publication number: 20020041884
    Abstract: The invention relates to viral formulations and related pharmaceutical products for use in gene therapy and/or vaccine applications. Especially preferred viral formulations disclosed herein are liquid adenovirus formulations, which show improved stability when stored in about the 2-8° C. range while also being compatible with parenteral administration. These formulations comprise a buffer, a sugar, a salt, a divalent cation, a non-ionic detergent, as well as a free radical scavenger and/or a chelating agent to inhibit free radical oxidation.
    Type: Application
    Filed: March 6, 2001
    Publication date: April 11, 2002
    Inventors: Robert K. Evans, David B. Volkin
  • Stabilized human papillomavirus formulations
    Patent number: 6358744
    Abstract: Human papillomavirus (HPV) antigen formulations are disclosed which prevent protein aggregation and show prolonged stability as aqueous solutions. These formulations comprise a salt (such as sodium chloride) and a non-ionic surfactant (Polysorbate 80 such as Tween 80®) in physiologically acceptable concentrations.
    Type: Grant
    Filed: July 24, 2000
    Date of Patent: March 19, 2002
    Assignee: Merck & Co., Inc.
    Inventors: David B. Volkin, Li Shi, Gautam Sanyal
  • Stabilizers for lyophilized vaccines
    Patent number: 6290967
    Abstract: Vaccine stabilizers, vaccine formulations and lyophilized vaccines with enhanced thermostability are disclosed. The vaccine formulations comprise an increased amount of a 6-carbon polyhydric alcohol (such as sorbitol), an increase amount of a disaccharide (such as sucrose) and an amount of a physiologically active buffer to adjust the pH from about 6.0 to about 7.0.
    Type: Grant
    Filed: June 3, 1998
    Date of Patent: September 18, 2001
    Assignee: Merck & Co., Inc.
    Inventors: David B. Volkin, Su-Pi Sheu, Carl J. Burke
  • Human papillomavirus vaccine with disassembled and reassembled virus-like particles
    Publication number: 20010021385
    Abstract: Human Papillomavirus vaccine formulations which contain virus-like particles (VLPs) can be made more stable and have an enhanced shelf-life, by treating the VLPs to a disassembly and reassembly process. Also provided are formulation buffers to long term stable storage of VLPs.
    Type: Application
    Filed: January 30, 2001
    Publication date: September 13, 2001
    Inventors: David B. Volkin, Henryk Mach, Li Shi
  • Human papillomavirus vaccine formulations
    Patent number: 6251678
    Abstract: New human papilloma virus (HPV) vaccine formulations exhibit enhanced long-term stability. Formulation components can include: virus-like particles (VLPs) absorbed onto aluminum, a salt, non-ionic surfactant, and a buffer. Additional formulations also contain a polymeric polyanionic stabilizer and a salt either in the presence or absence buffering agents and nonionic detergent.
    Type: Grant
    Filed: February 2, 2000
    Date of Patent: June 26, 2001
    Assignee: Merck & Co., Inc.
    Inventors: David B. Volkin, Li Shi, Henryk Mach
  • Human papilloma virus vaccine with disassembled and reassembled virus-like particles
    Patent number: 6245568
    Abstract: Human Papillomavirus vaccine formulations which contain virus-like particles (VLPs) can be made more stable and have an enhanced shelf-life, by treating the VLPs to a disassembly and reassembly process. Also provided are formulation buffers to long term stable storage of VLPs.
    Type: Grant
    Filed: March 13, 2000
    Date of Patent: June 12, 2001
    Assignee: Merck & Co., Inc.
    Inventors: David B. Volkin, Henryk Mach, Li Shi
  • Stabilizers for lyophilized mumps vaccines
    Patent number: 6051238
    Abstract: Vaccine stabilizers, vaccine formulations and lyophilized vaccines with enhanced thermostability are disclosed. The vaccine formulations comprise an increased amount of a 6-carbon polyhydric alcohol (such as sorbitol), an increase amount of a disaccharide (such as sucrose) and an amount of a physiologically active buffer to adjust the pH from about 6.0 to about 7.0.
    Type: Grant
    Filed: December 18, 1997
    Date of Patent: April 18, 2000
    Assignee: Merck & Co., Inc.
    Inventors: David B. Volkin, Carl J. Burke, Su-Pi Sheu
  • Rotavirus vaccine formulations
    Patent number: 5932223
    Abstract: The present invention provides novel liquid and lyophilized formulations of vaccines against rotavirus infection and methods of their preparation. The formulations include buffering agents appropriate for oral administration of rotavirus vaccines. The formulations also include compounds to stabilize of the vaccine compositions against loss of potency.
    Type: Grant
    Filed: September 26, 1997
    Date of Patent: August 3, 1999
    Assignee: Merck & Co., Inc.
    Inventors: Carl J. Burke, David B. Volkin